RealTime Dynamix™: Psoriasis US Q3 2018 Spotlight
Janssen’s Tremfya continues to post gains, but may soon face competition as Sun Dermatology readies for the launch of Ilumya (tildrakizumab), the second IL-23 inhibitor to be introduced in the US market. In the latest quarterly survey of 102 US dermatologists conducted in August 2018, the launch of Cimzia (certolizumab pegol) is benchmarked against other recent launches in psoriasis including Eli Lilly’s Taltz (ixekizumab), Ortho Dermatologics’ Siliq (brodalumab), and Tremfya (guselkumab). View complimentary highlights from Q3 report below.
Contact [email protected] for more information about the highlighted report or to see if your company already has access to the report series.
All company, brand or product names and logos in this document are trademarks of their respective holders.